Abstract： Objective To investigate the efficacy of insulin pump combination therapy in overweight and obese pa-tients with type 2 diabetes mellitus(T2DM)after short-term intensive insulin pump therapy.Methods The clinical data of 86 overweight and obese patients with a primary diagnosed of T2DM admitted to Zhangdian District People's Hospital from September 2022 to September 2023 were retrospectively selected.All patients received short-acting in-sulin pump intensive therapy for 1 week,and combined medication was performed after treatment.According to the difference of medication,the patients were divided into group A(n=43,metformin+insulin glargine)and group B(n=43,metformin+liraglutide).All patients were treated for more than 12 weeks.The blood glucose indexes,islet cell test results,weight loss,blood lipid indexes,and adverse reactions during medication were compared between the two groups.Results After 12 weeks of continuous administration,the fasting plasma glucose and 2-hour postprandial plasma glucose levels in group A were lower than those in group B,and the differences were statistically significant(all P<0.05).Group A body mass index,total cholesterol and triglyceride levels,islet beta cell function index were higher than group B,insulin resistance index is lower than that of group B,and the differences were statistically sig-nificant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For overweight and obese T2DM patients,after short-term intensive treatment with insulin pump,metformin-based coadministration of glycemic insulin helps to maintain the stability of blood glucose index and improve the patients'pancreatic islet function,whereas liraglutide has certain advantages in weight reduction as well as regulation of patients'lipid index.